Recombinant gonadotrophins in reproductive medicine: Gold standard for ovarian stimulation therapy in the 21st century

Reproductive BioMedicine Online

Volumn 11, Issue 5, 2005, Pages 535-536

  Ludwig, M ^a   Keck, Christoph ^b  

^a Reproduktionsmedizin und Gynäkologische Endokrinologie   (Switzerland)

^b Serono International SA   (Switzerland)

Author keywords

Ovarian stimulation; Purity; Recombinant human FSH; Safety; Urinary gonadotrophins

Indexed keywords

FERTILITY PROMOTING AGENT; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; MENOTROPHIN; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG MANUFACTURE; DRUG PURITY; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; NOTE; OVULATION INDUCTION; POSTMENOPAUSE; PREGNANCY RATE; STANDARD; TREATMENT OUTCOME;

EID: 28244481416     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61153-4     Document Type: Note

References (14)

1. Al-Inany H, Aboulghar M, Mansour R, Serour G 2003 Meta-analysis of recombinant versus urinary-derived FSH: an update. Human Reproduction 18, 305-313.
2. Andersen AN, Devroey P. Arce JC 2005 A randomized trial (MERIT) comparing highly purified menotrophin and recombinant FSH in IVF. Human Reproduction 20 (suppl. 1), O-054.
3. Balasch J, Barri PN 2001 Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective. Journal of Assisted Reproduction and Genetics 18, 45-55.
4. Daya S 2002 Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility and Sterility 77, 711-714.
5. Daya S, Ledger W, Auray JP et al. 2001 Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Human Reproduction 16, 2563-2569.
6. De Placido G, Alviggi C, Perino A et al. 2005 Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 20, 390-396.
7. Giudice E, Crisci C, Eshkol A, Papoian R 1994 Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. Human Reproduction 9, 2291-2299.
8. Ludwig M, Rabe T, Bühler K et al. 2004 Efficacy of recombinant human FSH in comparison to urinary HMG following a long down-regulation protocol - an analysis of 24,764 ART cycles in Germany. Journal für Reproduktionsmedizin und Endokrinologie 1, 284-288.
9. Marrs R, Meldrum D, Muasher S et al. 2004 Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
10. Matorras R, Recio V, Corcostegui B, Rodriguez-Escudero FJ 2000 Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoa. Human Reproduction 15, 1231-1234.
11. Romeu A, Balasch J, Ruiz Balda JA et al. 2003 Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system. Journal of Assisted Reproduction and Genetics 20, 294-300.
12. Silverberg K, Daya S, Auray JP et al. 2002 Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertility and Sterility 77, 107-113.
13. van de Weijer BH, Mulders JW, Bos ES et al. 2003 Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive BioMedicine Online 7, 547-557.
14. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F 2003 Effectiveness of human menopausal gonadotrophin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertility and Sterility 80, 1086-1093.